AKT1 and myelodysplastic syndrome: As expected, we found that SETBP1 inhibition downregulated the PI3K-AKT pathway (Fig. 6B), while overexpression of SETBP1 activated the PI3K-AKT signaling pathway in MDS-L cells (Fig. 6C).